{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:49:47Z","timestamp":1791924587999,"version":"4.3.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1093\/eurheartj\/ehs023","type":"journal-article","created":{"date-parts":[[2012,4,17]],"date-time":"2012-04-17T00:44:51Z","timestamp":1334623491000},"page":"1142-1149","source":"Crossref","is-referenced-by-count":177,"title":["Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial"],"prefix":"10.1093","volume":"33","author":[{"given":"Maartje E.","family":"Visser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Wagener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda F.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Geary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne M.","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich H.W.","family":"Beuers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aart J.","family":"Nederveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Verheij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke D.","family":"Trip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick C.G.","family":"Basart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S.G.","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,5]]},"reference":[{"key":"key\n\t\t\t\t20170515130903_EHS023C1","first-page":"3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment III) final report","volume-title":"Circulation","author":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment III)","year":"2002"},{"key":"key\n\t\t\t\t20170515130903_EHS023C2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study","volume":"19","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"key\n\t\t\t\t20170515130903_EHS023C3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/MOL.0b013e32825a6773","article-title":"The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis","volume":"18","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"key\n\t\t\t\t20170515130903_EHS023C4","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170515130903_EHS023C5","doi-asserted-by":"crossref","first-page":"89C","DOI":"10.1016\/j.amjcard.2006.02.030","article-title":"Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force","volume":"97","year":"2006","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170515130903_EHS023C6","first-page":"601","volume-title":"Cardiovascular Therapeutic Applications in Antisense Drug Technology; Principles, Strategies and Applications","year":"2007","edition":"2nd ed"},{"key":"key\n\t\t\t\t20170515130903_EHS023C7","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2009.11.069","article-title":"Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy","volume":"55","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170515130903_EHS023C8","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.105.606442","article-title":"Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B","volume":"114","year":"2006","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515130903_EHS023C9","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170515130903_EHS023C10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515130903_EHS023C11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MOL.0b013e32833af4c1","article-title":"Apolipoprotein B synthesis inhibition: results from clinical trials","volume":"21","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"key\n\t\t\t\t20170515130903_EHS023C12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","article-title":"Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group","volume":"303","year":"1991","journal-title":"Br Med J"},{"key":"key\n\t\t\t\t20170515130903_EHS023C13","first-page":"1380","article-title":"Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states","volume":"2","year":"1969","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170515130903_EHS023C14","doi-asserted-by":"crossref","first-page":"a2423","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"337","year":"2008","journal-title":"Br Med J"},{"key":"key\n\t\t\t\t20170515130903_EHS023C15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cll.2006.07.006","article-title":"Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy","volume":"26","year":"2006","journal-title":"Clin Lab Med"},{"key":"key\n\t\t\t\t20170515130903_EHS023C16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00330-010-1905-5","article-title":"The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis","volume":"21","year":"2011","journal-title":"Eur Radiol"},{"key":"key\n\t\t\t\t20170515130903_EHS023C17","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/jmri.21837","article-title":"Reproducibility of 3.0 Tesla magnetic resonance spectroscopy for measuring hepatic fat content","volume":"30","year":"2009","journal-title":"J Magn Reson Imaging"},{"key":"key\n\t\t\t\t20170515130903_EHS023C18","doi-asserted-by":"crossref","first-page":"E462","DOI":"10.1152\/ajpendo.00064.2004","article-title":"Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population","volume":"288","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"key\n\t\t\t\t20170515130903_EHS023C19","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","year":"2005","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170515130903_EHS023C20","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","year":"2004","journal-title":"J Am Med Assoc"},{"key":"key\n\t\t\t\t20170515130903_EHS023C21","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial","volume":"295","year":"2006","journal-title":"J Am Med Assoc"},{"key":"key\n\t\t\t\t20170515130903_EHS023C22","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.amjcard.2010.01.003","article-title":"Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density-lipoprotein cholesterol in patients with familial hypercholesterolemia","volume":"105","year":"2010","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170515130903_EHS023C23","first-page":"898","article-title":"A randomized, double-blind, placebo-controlled study to assess efficacy and safety of mipomersen as add-on therapy in heterozygous familial hypercholesterolemia patients with coronary artery disease","volume":"31","year":"2010","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170515130903_EHS023C24","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1093\/eurheartj\/ehr148","article-title":"Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia","volume":"32","year":"2011","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170515130903_EHS023C25","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1194\/jlr.M011791","article-title":"Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice","volume":"52","year":"2011","journal-title":"J Lipid Res"},{"key":"key\n\t\t\t\t20170515130903_EHS023C26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.108.786822","article-title":"Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice","volume":"118","year":"2008","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515130903_EHS023C27","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ejim.2010.03.015","article-title":"The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients","volume":"21","year":"2010","journal-title":"Eur J Intern Med"},{"key":"key\n\t\t\t\t20170515130903_EHS023C28","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.amjcard.2008.02.061","article-title":"Efficacy of rosuvastatin (5 and 10 mg) twice a week in patients intolerant to daily statins","volume":"101","year":"2008","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170515130903_EHS023C29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.amjcard.2008.09.095","article-title":"Once-a-week rosuvastatin (2.5\u201320 mg) in patients with a previous statin intolerance","volume":"103","year":"2009","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170515130903_EHS023C30","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1194\/jlr.M002915","article-title":"Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia","volume":"51","year":"2010","journal-title":"J Lipid Res"},{"key":"key\n\t\t\t\t20170515130903_EHS023C31","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1194\/jlr.M400492-JLR200","article-title":"An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis","volume":"46","year":"2005","journal-title":"J Lipid Res"},{"key":"key\n\t\t\t\t20170515130903_EHS023C32","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1185\/030079906X104696","article-title":"Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study","volume":"22","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"key\n\t\t\t\t20170515130903_EHS023C33","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170515130903_EHS023C34","first-page":"131","article-title":"Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia","volume":"23","year":"2004","journal-title":"Indian J Gastroenterol"},{"issue":"Suppl. 1","key":"key\n\t\t\t\t20170515130903_EHS023C35","first-page":"S17","article-title":"Pathophysiology of nonalcoholic steatohepatitis","volume":"40","year":"2006","journal-title":"J Clin Gastroenterol"},{"key":"key\n\t\t\t\t20170515130903_EHS023C36","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1467-789X.2009.00657.x","article-title":"Non-alcoholic fatty liver disease from pathogenesis to management: an update","volume":"11","year":"2010","journal-title":"Obes Rev"},{"key":"key\n\t\t\t\t20170515130903_EHS023C37","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1194\/jlr.M300508-JLR200","article-title":"Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity","volume":"45","year":"2004","journal-title":"J Lipid Res"},{"key":"key\n\t\t\t\t20170515130903_EHS023C38","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.atherosclerosis.2007.05.003","article-title":"Molecular diagnosis of hypobetalipoproteinemia: an ENID review","volume":"195","year":"2007","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20170515130903_EHS023C39","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jhep.2005.06.018","article-title":"Hepatic steatosis and insulin resistance: does etiology make a difference?","volume":"44","year":"2006","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20170515130903_EHS023C40","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s00125-011-2157-x","article-title":"Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia","volume":"54","year":"2011","journal-title":"Diabetologia"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/33\/9\/1142\/17050758\/ehs023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T09:09:22Z","timestamp":1713863362000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-lookup\/doi\/10.1093\/eurheartj\/ehs023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2012,5]]},"published-print":{"date-parts":[[2012,5]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehs023","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}